[ XXXX and sensitivity of pathogens to antimycotics].

@entity1 @entity363 @entity1449 @entity5213 @entity5897 @entity6923 @entity2380 @entity7408 @entity3102 @entity2059 @entity5132 @entity281 @entity15231 @entity375 @entity5638 @entity8701
OBJECTIVE: Analysis of the prevalence and species representation of pathogenic @entity375 in @entity1 with @entity363 . Determination of in vitro susceptibility of @entity375 isolates to clinically used antimycotic agents. DESIGN: A retrospective clinical study of @entity1 with positive vaginal cultures for the presence of pathogenic @entity375 species. SETTING: I. gynekologicko-p  rodn  cka klinika LF UK a FN, Zochova 7,811 03 Bratislava, Slovensk   republika. METHODS: Identification of @entity375 pathogens on the chromogenic medium CHROMagar CANDIDA and with API-CANDIDA identification system. In vitro susceptibility assays of clinical @entity375 isolates to antifungal agents using the plate dilution method, NCCLS method and ATB-FUNGUS test system. RESULTS: The highest prevalence of @entity15231 was found in @entity1 aged between 20-30 years. @entity5132 was the most commonly identified species of pathogenic @entity375 (87.4%). Of the non-albicans species, @entity7408 (6.3%) was the most prevalent species. @entity7408 and C. krusei clinical isolates were found to be generally less susceptible to several antifungals in vitro as compared to @entity5132 strains. A minimal number of resistant @entity375 isolates was observed for @entity5213 , @entity1449 and @entity8701 . A relatively high number of resistant strains was observed for some other @entity5638 antifungals ( @entity5897 , @entity3102 , @entity2059 , @entity2380 ). CONCLUSION: A successful treatment of @entity281 requires the results of the microbiological analyses. They will bring evidence to a physician of the presence and fate of the pathogen, of its sensitivity to antifungals, both of which are essential for the rational and successful therapy of @entity6923 .
